ISOPP CAPhO 2025 Symposium: Sponsored Breakfast Symposium Pfizer Canada - Espresso Shot Learning: Hot Topics and Updates in Lung and Urothelial Cancers

Join us for an engaging symposium offering insights into the latest developments in lung and urothelial cancers through informative presentations, panel discussions, and interactive Q&A sessions. This session will feature a panel of pharmacists sharing expert perspectives and practical tips on patient counseling, as well as the monitoring and management of adverse events related to first-line treatments for ALK-positive non-small cell lung cancer (NSCLC) and locally advanced/metastatic urothelial cancer (la/mUC).

After attending this symposium, participants will be able to:

• Describe the changing first-line treatment landscape in locally advanced/metastatic urothelial cancer (la/mUC)
• Implement practical strategies to identify and manage adverse events in patients treated with immunotherapy with or without an antibody-drug conjugate (ADC) for la/mUC
• Counsel patients regarding adverse events associated with first-line treatment options for ALK-positive non-small cell lung cancer (NSCLC)
• Appropriately monitor patients treated with ALK inhibitors for ALK-positive NSCLC and manage associated toxicities